Advanced glycation end product carboxymethyl-lysine and risk of incident peripheral artery disease in older adults: The Cardiovascular Health Study

Parveen K. Garg, Mary L. Biggs, Joshua Barzilay, Luc Djousse, Calvin H Hirsch, Joachim H. Ix, Jorge R. Kizer, Russell P. Tracy, Anne B. Newman, David S. Siscovick, Kenneth J. Mukamal

Research output: Contribution to journalLetter

Abstract

Carboxymethyl-lysine is an advanced glycation end product that is detectable in the serum. Higher carboxymethyl-lysine levels have been associated with increased risk of coronary heart disease, stroke and cardiovascular mortality. We determined whether high carboxymethyl-lysine levels are also associated with the risk of peripheral artery disease in Cardiovascular Health Study participants who were all aged 65 years and older at baseline. Multivariate Cox proportional hazards models were used to determine the association of baseline carboxymethyl-lysine levels with incident peripheral artery disease in 3267 individuals followed for a median length of 10.0 years. A total of 157 cases of incident peripheral artery disease occurred during follow-up. No significant relationship between carboxymethyl-lysine and risk of peripheral artery disease was found (hazard ratio per standard deviation increment = 1.03; 95% confidence interval = 0.87, 1.23).

Original languageEnglish (US)
JournalDiabetes and Vascular Disease Research
DOIs
StatePublished - Jan 1 2019

Keywords

  • Advanced glycation end products
  • ankle–brachial index
  • inflammation
  • peripheral artery disease

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Advanced glycation end product carboxymethyl-lysine and risk of incident peripheral artery disease in older adults: The Cardiovascular Health Study'. Together they form a unique fingerprint.

  • Cite this